pdufa.bio

LINZESS (Iinaclotide)

Updated ยทnext FDA decision on the calendar

LINZESS (Iinaclotide) The FDA approved it on May 27, 2026. 2 FDA decisions on record below. Every date links its source.

ABBV catalyst hub · IRWD catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 2 catalyst events for this program: 0 upcoming and 2 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

PDUFA · May 27, 2026 ✓ ApprovedABBVPDUFA · May 27, 2026 ✓ ApprovedIRWD

Questions

When is LINZESS (Iinaclotide)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for LINZESS (Iinaclotide); 2 FDA decisions are on record below.

What happened at LINZESS (Iinaclotide)'s most recent FDA decision?

On May 27, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has LINZESS (Iinaclotide) been approved by the FDA?

Yes. The FDA approved an application for LINZESS (Iinaclotide) on May 27, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.